Source: International Congress 2015 – COPD: chronic disease and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bogdana Basina (Dnipropetrovsk, Ukraine), Bogdana Basina, Tetyana Pertseva, Lyudmila Konopkina. What is the best biomarker of COPD stability?. Eur Respir J 2015; 46: Suppl. 59, 693

Member's Comments

No comment yet.

Related content which might interest you: Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Are there any differences between Tunisian and European COPD phenotypes? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 What should be part of a comprehensive assessment of COPD? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Clinical and inflammatory characteristics of 'unreported' COPD exacerbations Source: Annual Congress 2013 –COPD mechanisms Year: 2013 The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU Year: 2013 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 GOLD and phenotypes: The new Czech COPD guidelines Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Can red blood cell morphology be an indicator for COPD exacerbations? Source: International Congress 2014 – Markers Year: 2014 Evaluation of the GOLD 2011 severity criteria across the COPD spectrum Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Importance of the initial behaviour of patients in avoiding late recovery from COPD exacerbations Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014